4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Ardelyx
- Study ID
- NCT06553547
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - 11 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tenapanor — DRUGTenapanor 5 mg/mL solution
- Placebo — DRUGMatching Placebo solution
Study Details
This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.
Key Dates
- Start date
- Jul 24, 2024
- Status verified
- Jun 2026
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 72 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Tenapanor Cohort 1Tenapanor 2 mg BID
- Experimental: Tenapanor Cohort 2Tenapanor 5 mg BID
- Experimental: Tenapanor Cohort 3Tenapanor 10 mg BID
- Experimental: Tenapanor Cohort 4Tenapanor 15 mg BID
- Experimental: Tenapanor Cohort 5Tenapanor 20 mg BID
- Experimental: Tenapanor Cohort 6Tenapanor 25 mg BID
- Placebo Comparator: PlaceboMatching placebo
Primary Outcome Measure
Average weekly SBM (week 4) [ Time Frame: 4 weeks ]
Locations (20)
Find similar trials in Little Rock, AR
By research site
Applied Research Center of Arkansas· Little Rock, ARConnecticut Children's Medical Center· Hartford, CTValencia Medical and Research Center· Miami, FLWaterway Research & Associates Corp.· Miami, FLOrlando Health, Inc.- APH Center for Digestive Health and Nutrition· Orlando, FLFlorida Pharmaceutical Research and Associates, Inc.· South Miami, FL
Related Studies
- Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CPHASE3 · Enrolling By Invitation · Ardelyx · Foley, Alabama